Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
49 /100
MEDIUM RISK
Score updated Aug 28, 2026

CNSP — CNS Pharmaceuticals, Inc. Dilution Risk Tracker

Track CNSP dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track CNSP — Get alerts when the score changes →

As of August 28, 2026, CNS Pharmaceuticals, Inc. (CNSP) has a DilutionWatch DilutionScore of 49/100, rated MEDIUM dilution risk. CNS Pharmaceuticals, Inc. has a market capitalization of $7.95M, 1.46M shares outstanding, 10 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
60
💰 Cash Runway
40
📊 Float Risk
12
⚠️ Warrant Exposure
40
🔄 Convertible Debt
40

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 0%
No significant dilution signals detected for CNSP.
🔔 Track CNSP — Get forecast alerts →

Market Data

Market Cap$7.95M
Shares Outstanding1.46M
Float1.45M
Cash$19.98M
Debt$449.9K
Short InterestN/A

Institutional Holdings

10 institutional holders · 124.4K shares
#1 Stonepine Capital Management, LLC 48.8K shares
#2 Ikarian Capital, LLC 45.8K shares
#3 DRW Securities, LLC 15.4K shares
+ 7 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest11.4K
Days to Cover1.2
% of Float0.8%
FINRA data as of Jul 31, 2026

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2025-12-31
xbrl XBRL WARRANT 2025-12-31
8-K 8K EVENT 2026-05-04
4 INSIDER TRANSACTION 2026-03-04
3 FORM3 2026-03-04
Full SEC filing analysis available with free account

Recent News

No recent news

Factual CNSP Dilution Snapshot

CNS Pharmaceuticals, Inc. (CNSP) has a DilutionScore of 49/100, rated Medium dilution risk. Score date: August 28, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

Track CNSP Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking CNSP — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,024+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for CNSP
CNSP FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.